Relative efficacies of omega-3 polyunsaturated fatty acids in reducing expression of key proteins in a model system for studying osteoarthritis

Osteoarthritis and Cartilage

Volumn 17, Issue 7, 2009, Pages 896-905

  Zainal, Z ^a   Longman, A J ^a   Hurst, S ^a   Duggan, K ^a   Caterson, B ^a   Hughes, C E ^a   Harwood, J L ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Chondrocyte cultures; Inflammation; Omega 3(n 3) polyunsaturated fatty acids; Osteoarthritis; Proteinases

Indexed keywords

ADAM PROTEIN; ARACHIDONIC ACID; COLLAGENASE 3; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; LINOLENIC ACID; MESSENGER RNA; OMEGA 3 FATTY ACID; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; LACTIC ACID; MATRIX METALLOPROTEINASE; PEPTIDE HYDROLASE;

ANIMAL CELL; ARTICLE; CARTILAGE CELL; CELL CULTURE; CONTROLLED STUDY; COW; DIET SUPPLEMENTATION; DIETARY INTAKE; DRUG EFFICACY; DRUG MECHANISM; ENZYME INDUCTION; GENE EXPRESSION REGULATION; INCUBATION TIME; INFLAMMATION; MOLECULAR MECHANICS; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ANIMAL; ARTICULAR CARTILAGE; BIOSYNTHESIS; CATTLE; DISEASE MODEL; FORELIMB; METABOLISM;

ADAM PROTEINS; ANIMALS; CARPUS, ANIMAL; CARTILAGE, ARTICULAR; CATTLE; CELLS, CULTURED; CHONDROCYTES; CYCLOOXYGENASE 2; CYTOKINES; DISEASE MODELS, ANIMAL; FATTY ACIDS, OMEGA-3; INTERLEUKIN-1ALPHA; LACTIC ACID; MATRIX METALLOPROTEINASES; OSTEOARTHRITIS; PEPTIDE HYDROLASES; RNA, MESSENGER;

EID: 67349266985     PISSN: 10634584     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.joca.2008.12.009     Document Type: Article

References (48)

1. Rowan A.D. Cartilage catabolism in arthritis: factors that influence homeostasis. Rev Mol Med 3 (2001) 1-20
2. Scott D.L., Shipley M., Dawson A., Edwards S., Symmons D.P., and Woolf A.D. The clinical management of rheumatoid arthritis and osteoarthritis: strategies for improving clinical effectiveness. British J Rheumatol 37 (1998) 546-554
3. Mow V.C., Setton L.S., Guilak F., and Ratcliffe A. Mechanical factors in articular cartilage and their role in osteoarthritis. In: Kuettner K., Goldberg V., and Rosemont I. (Eds). Osteoarthritis Disorders. American Acad Orthopedic Surgeons (1995) 147-171
4. Mort J.S., and Billington C.J. Articular cartilage and changes in arthritis: matrix degradation. Arthritis Res 3 (2001) 337-341
5. Hughes C.E., Little C.B., Buttner F.H., Bartnik E., and Caterson B. Differential expression of aggrecanase and matrix metalloproteinase activity in chondrocytes isolated from bovine and porcine articular cartilage. J Biol Chem 273 (1998) 30576-30585
6. Watanabe H., Yoshihiko Y., and Kimata K. Roles of aggrecan: a large chondroitin sulphate proteoglycan, in cartilage structure and function. J Biochem (Tokyo) 124 (1998) 687-693
7. Sandy J.D., Westling J., Kenagy R.D., Iruela-Arispe P.L., Verscharen C., Rodriguez-Mazaneque J.C., et al. Versican VI proteolysis in human aorta in vivo occurs at the Glu441-Ala442 bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4. J Biol Chem 276 (2001) 13372-13378
8. Abbaszade I., Liu R.Q., Yang F., Rosenfeld S.A., Ross O.H., Link J.R., et al. Cloning and characterisation of ADAMTS11, an aggrecanase from the ADAMTS family. J Biol Chem 274 (1999) 23443-23450
9. Arner E.C., Pratta M.A., Trzaskos J.M., Decicco C.P., and Tortorella M.D. Generation and characterisation of aggrecanase. A soluble, cartilage-derived aggrecan-degrading activity. J Biol Chem 274 (1999) 6594-6601
10. Glasson S.S., Askew R., Sheppard B., Carito B., Blanche T., Ma H.-L., et al. Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice. Arthritis Rheum 50 (2004) 2547-2558
11. Stanton H., Frazer M., Rogerson C.J., East S.B., Golub K.E., Lawlor C.T., et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 434 (2005) 648-652
12. Glasson S.S., Askew R., Sheppard B., Carito B., Blanche T., Ma H.-L., et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature 434 (2005) 644-648
13. Tortorella M.D., Malfait A.M., Deccico C., and Arner E. The role of ADAMTS-4 (aggrecanase-1) and ADAMTS-5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cartilage 9 (2001) 539-552
14. Gendron C., Kashiwagi M., Lim N.H., Enghild J.J., Thogersen I.B., Hughes C., et al. Proteolytic activities of human ADAMTS-5; comparative studies with ADAMTS-4. J Biol Chem 282 (2007) 18294-18306
15. Kevorkian L., Young D.A., Darrah C., Donell S.T., Shepstone L., Porter S., et al. Expression profiling of metalloproteinases and their inhibitors in cartilage. Arthritis Rheum 50 (2004) 131-141
16. Clarke I.M., and Parker A.E. Metalloproteinases: their role in arthritis and potential as therapeutic targets. Expert Opin Ther Targets 7 (2005) 19-34
17. Walakovits lA., Moore V.L., Bhardwaj N., Gallick G.S., and Lark M.W. Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and post-traumatic knee injury. Arthritis Rheum 35 (1992) 35-42
18. Cawston T. Matrix metalloproteinases and TIMPS: properties and implications for the rheumatic diseases. Mol Med Today 9 (1998) 130-137
19. Calder P.C. n-3 Polyunsaturated fatty acids, inflammation and immunity: pouring oil on troubled waters or another fishy tale?. Nutri Res 21 (2001) 309-341
20. Gurr M.I., Harwood J.L., and Frayn K.N. Lipid Biochemistry. Fifth edn (2002), Blackwells Scientific, Oxford
21. Harwood J.L., and Caterson B. Dietary omega-3 polyunsaturated fatty acids and inflammation. Lipid Technol 18 (2006) 7-10
22. Serhan C.H., Gotlinger K., Hong S., and Arita M. Resolvins, docosatrienes and neuroprotectins, novel omega-3-derived mediators and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. Prostaglandins Other Lipid Mediat 73 (2004) 155-172
23. Simopoulos A.P. Omega-3 fatty acids in inflammation and autoimmune diseases. J Am Coll Nutr 21 (2002) 495-505
24. Simopoulos A.P. Essential fatty acids in health and chronic disease. Am J Clin Nutr 70 (1999) 560-569
25. Dubois R.N., Abramson S.B., Crofford A., Gupta R., Simon L.S., Van de Putte L.B.A., et al. Cyclooxygenase in biology and disease. FASEB J 12 (1998) 1063-1073
26. Fiorucci S., Meli R., Bucci M., and Cirino G. Dual inhibitors of cyclooxygenase and 5-lipoxygenase. A new avenue in anti-inflammatory therapy?. Biochem Pharmacol 62 (2001) 1433-1438
27. Smith C., Zhang Y., Koboldt C.M., Muhammad J., Zweifel B.S., Shaffer A., et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A 95 (1998) 13313-13318
28. Vane J.R., Bakhle Y.S., and Botting R.M. Cyclooxygenase 1 and 2. Annu Rev Pharmacol Toxicol 38 (1998) 97-120
29. Mitchell J.A., and Warner T.D. Cyclooxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. Brit J Pharmacol 128 (1999) 1121-1132
30. Drazen J.M. A lesson in unexpected problems. New Engl J Med 352 (2005) 1131-1132
31. Cunnane S.C. Problems with essential fatty acids: time for a new paradigm?. Prog Lipid Res 42 (2003) 544-568
32. ISSFAL. Recommendation for intake of polyunsaturated fatty acids in healthy adults. ISSFAL Newsl 11 (2004) 12-25
33. Morris M.C., Evans D.A., Bienias J.L., Tanguey C.C., Bennett D.A., Wilson R.S., et al. Consumption of fish and n-3 fatty acids and risk of incident Alzheimer disease. Arch Neurol 60 (2003) 940-946
34. Garbus J., De Luca H.F., Loomans M.E., and Strong F.M. The rapid incorporation of phosphate in mitochondrial lipids. J Biol Chem 238 (1963) 59-63
35. Arkill K.P., and Winlove C.P. Fatty acid transport in articular cartilage. Arch Biochem Biophys 456 (2006) 71-78
36. Zainal Z. How can palm oil be modified to give improved dietary benefits?. Ph.D. thesis, University of Cardiff, UK, 2005.
37. Aydelotte M.B., Raiss R.X., Caterson B., and Kuettner K.E. Influence of interleukin-1 on the morphology and proteoglycan metabolism of cultured bovine articular chondrocytes. Connect Tissue Res 28 (1992) 143-159
38. Brooks P., Emery P., Evans J.F., Fenner H., Hawkey C.J., and Patrono C.J. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology 38 (1999) 779-788
39. Pelletier J.H., Alaaeddine N., and Pelletier J.P. Cytokines and their role in the pathophysiology of osteoarthritis. Frontiers Bioscience 4 (1999) 694-703
40. Calder P.C. n-3 fatty acids and cardiovascular disease: evidence explained and mechanisms explored. Clin Sci 107 (2004) 1-11
41. Harwood J.L. Human dietary requirements. In: Gunstone F.D., Harwood J.L., and Dijkstra A.J. (Eds). The Lipid Handbook. Third edn (2007), Taylor and Francis, Boca Raton, Fl 703-710
42. Kim H.H., Cho S., Lee S., Kim K.H., Cho K.H., Eun H.C., et al. Photoprotective and anti-skin-aging effects of eicosapentaenoic acid in human skin in vitro. J Lipid Res 47 (2006) 921-930
43. E inhibition. Proc Natl Acad Sci U S A 103 (2006) 15184-15189
44. Clarke S.D. Polyunsaturated fatty acid regulation of gene transcription: a molecular mechanism to improve the metabolic syndrome. J Nutr 131 (2001) 1129-1132
45. Jump D.B. The biochemistry of n-3 polyunsaturated fatty acids. J Biol Chem 277 (2002) 8755-8758
46. Hurst S. n-3 polyunsaturated fatty acid effects on inflammatory mediator activity and intracellular signalling pathways in chondrocyte metabolism. Ph.D. thesis, University of Cardiff, UK, 2004.
47. Qi B., Frazer T., Mugford S., Dobson G., Sayanova O., Butler J., et al. Production of very long chain polyunsaturated omega-3 and omega-6 fatty acids in plants. Nature Biotechnol 22 (2004) 739-745
48. Wu G., Truksa M., Datla N., Vrinten P., Bauer J., Zank T., et al. Stepwise metabolic engineering of economically significant amounts of very long chain polyunsaturated fatty acids in seeds of Brassica juncea. Nature Biotechnol 23 (2005) 1013-1017